Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide

In patients with metastatic castrate‐resistant prostate cancer (mCRPC), circulating tumor DNA (ctDNA) analysis offers novel opportunities for the development of non‐invasive biomarkers informative of treatment response with novel agents targeting the androgen‐receptor (AR) pathway, such as abiratero...

Descripción completa

Detalles Bibliográficos
Autores principales: Belic, Jelena, Graf, Ricarda, Bauernhofer, Thomas, Cherkas, Yauheniya, Ulz, Peter, Waldispuehl‐Geigl, Julie, Perakis, Samantha, Gormley, Michael, Patel, Jaymala, Li, Weimin, Geigl, Jochen B., Smirnov, Denis, Heitzer, Ellen, Gross, Mitchell, Speicher, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Tumor Markers and Signatures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099279/
https://www.ncbi.nlm.nih.gov/pubmed/29574703
http://dx.doi.org/10.1002/ijc.31397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099279/
https://www.ncbi.nlm.nih.gov/pubmed/29574703
http://dx.doi.org/10.1002/ijc.31397

Ejemplares similares